

# Gerhard Christofori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6557266/publications.pdf>

Version: 2024-02-01

101  
papers

18,666  
citations

28274

55  
h-index

34986

98  
g-index

102  
all docs

102  
docs citations

102  
times ranked

25234  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hierarchy of TGF $\beta$ 2/SMAD, Hippo/YAP/TAZ, and Wnt/ $\beta$ 2-catenin signaling in melanoma phenotype switching. <i>Life Science Alliance</i> , 2022, 5, e202101010.	2.8	7
2	Tracking and characterization of partial and full epithelial-mesenchymal transition cells in a mouse model of metastatic breast cancer. <i>STAR Protocols</i> , 2022, 3, 101438.	1.2	0
3	Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression. <i>Oncogene</i> , 2021, 40, 12-27.	5.9	17
4	Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. <i>British Journal of Cancer</i> , 2021, 125, 164-175.	6.4	177
5	USP29-mediated HIF1 $\beta$ stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis. <i>Oncogenesis</i> , 2021, 10, 52.	4.9	33
6	Parsing $\beta$ 2-catenin $\beta$ cell adhesion and Wnt signaling functions in malignant mammary tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	17
7	The interactions of Bcl9/Bcl9L with $\beta$ 2-catenin and Pygopus promote breast cancer growth, invasion, and metastasis. <i>Oncogene</i> , 2021, 40, 6195-6209.	5.9	14
8	YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e14351.	6.9	204
9	The long non-coding RNA ET-20 mediates EMT by impairing desmosomes in breast cancer cells. <i>Journal of Cell Science</i> , 2021, 134, .	2.0	9
10	Distinct contributions of partial and full EMT to breast cancer malignancy. <i>Developmental Cell</i> , 2021, 56, 3203-3221.e11.	7.0	160
11	Histone deacetylases, Mbd3/NuRD, and Tet2 hydroxylase are crucial regulators of epithelial $\beta$ mesenchymal plasticity and tumor metastasis. <i>Oncogene</i> , 2020, 39, 1498-1513.	5.9	23
12	The cross-talk between the Hippo signaling pathway and autophagy: implications on physiology and cancer. <i>Cell Cycle</i> , 2020, 19, 2563-2572.	2.6	11
13	LATS1-Beclin1 mediates a non-canonical connection between the Hippo pathway and autophagy. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1757378.	0.7	2
14	A dual role of Irf1 in maintaining epithelial identity but also enabling EMT and metastasis formation of breast cancer cells. <i>Oncogene</i> , 2020, 39, 4728-4740.	5.9	15
15	A Pygopus 2-Histone Interaction Is Critical for Cancer Cell Dedifferentiation and Progression in Malignant Breast Cancer. <i>Cancer Research</i> , 2020, 80, 3631-3648.	0.9	11
16	Guidelines and definitions for research on epithelial $\beta$ mesenchymal transition. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 341-352.	37.0	1,195
17	Inferring signalling dynamics by integrating interventional with observational data. <i>Bioinformatics</i> , 2019, 35, i577-i585.	4.1	5
18	Targeting Cancer Cell Metastasis by Converting Cancer Cells into Fat. <i>Cancer Research</i> , 2019, 79, 5471-5475.	0.9	29

#	ARTICLE	IF	CITATIONS
19	A Hierarchical Regulatory Landscape during the Multiple Stages of EMT. <i>Developmental Cell</i> , 2019, 48, 539-553.e6.	7.0	67
20	Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells. <i>BMC Cancer</i> , 2019, 19, 312.	2.6	13
21	LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function. <i>Nature Communications</i> , 2019, 10, 5755.	12.8	36
22	Gain Fatâ€™Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis. <i>Cancer Cell</i> , 2019, 35, 17-32.e6.	16.8	205
23	A Transgenic MMTV-Flippase Mouse Line for Molecular Engineering in Mammary Gland and Breast Cancer Mouse Models. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 39-45.	2.7	5
24	Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front. <i>American Journal of Pathology</i> , 2018, 188, 1276-1288.	3.8	28
25	A kinome-wide high-content siRNA screen identifies MEK5â€™ERK5 signaling as critical for breast cancer cell EMT and metastasis. <i>Oncogene</i> , 2018, 37, 4197-4213.	5.9	58
26	The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. <i>Oncogenesis</i> , 2018, 7, 73.	4.9	63
27	Foxf2 plays a dual role during transforming growth factor beta-induced epithelial to mesenchymal transition by promoting apoptosis yet enabling cell junction dissolution and migration. <i>Breast Cancer Research</i> , 2018, 20, 118.	5.0	19
28	PyMT-1099, a versatile murine cell model for EMT in breast cancer. <i>Scientific Reports</i> , 2018, 8, 12123.	3.3	15
29	miR-1199-5p and Zeb1 function in a double-negative feedback loop potentially coordinating EMT and tumour metastasis. <i>Nature Communications</i> , 2017, 8, 1168.	12.8	50
30	TFAP2A is a component of the ZEB1/2 network that regulates TGF $\beta$ 1-induced epithelial to mesenchymal transition. <i>Biology Direct</i> , 2017, 12, 8.	4.6	28
31	A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGF $\beta$ 2 receptor. <i>Oncotarget</i> , 2016, 7, 25983-26002.	1.8	20
32	Epithelialâ€™mesenchymal transition (EMT) and metastasis: yes, no, maybe?. <i>Current Opinion in Cell Biology</i> , 2016, 43, 7-13.	5.4	406
33	Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy. <i>Cell Reports</i> , 2016, 15, 1161-1174.	6.4	163
34	The Rip1Tag2 Transgenic Mouse Model. <i>Methods in Molecular Biology</i> , 2016, 1464, 151-161.	0.9	3
35	The relevance of EMT in breast cancer metastasis: Correlation or causality?. <i>FEBS Letters</i> , 2015, 589, 1577-1587.	2.8	172
36	Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model. <i>Clinical Cancer Research</i> , 2015, 21, 4856-4867.	7.0	25

#	ARTICLE	IF	CITATIONS
37	Junctional adhesion molecule B interferes with angiogenic VEGF/VEGFR2 signaling. <i>FASEB Journal</i> , 2015, 29, 3411-3425.	0.5	12
38	An immature B cell population from peripheral blood serves as surrogate marker for monitoring tumor angiogenesis and anti-angiogenic therapy in mouse models. <i>Angiogenesis</i> , 2015, 18, 327-345.	7.2	10
39	PI3K signalling is required for a TGF $\beta$ -induced epithelial $\rightarrow$ mesenchymal-like transition (EMT-like) in human melanoma cells. <i>Experimental Dermatology</i> , 2015, 24, 22-28.	2.9	67
40	Tead2 expression levels control Yap/Taz subcellular distribution, zyxin expression, and epithelial-mesenchymal transition. <i>Journal of Cell Science</i> , 2014, 127, 1523-36.	2.0	113
41	VEGF-Mediated Angiogenesis Links EMT-Induced Cancer Stemness to Tumor Initiation. <i>Cancer Research</i> , 2014, 74, 1566-1575.	0.9	170
42	LIM-homeobox gene 2 promotes tumor growth and metastasis by inducing autocrine and paracrine PDGF $\beta$ signaling. <i>Molecular Oncology</i> , 2014, 8, 401-416.	4.6	53
43	Rebuilding cancer metastasis in the mouse. <i>Molecular Oncology</i> , 2013, 7, 283-296.	4.6	115
44	Paralemmin-1 is expressed in lymphatic endothelial cells and modulates cell migration, cell maturation and tumor lymphangiogenesis. <i>Angiogenesis</i> , 2013, 16, 795-807.	7.2	14
45	Sprouty2 expression controls endothelial monolayer integrity and quiescence. <i>Angiogenesis</i> , 2013, 16, 455-468.	7.2	13
46	Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by Controlling Ezh2 Expression and Epigenetic Reprogramming. <i>Cancer Cell</i> , 2013, 23, 768-783.	16.8	415
47	Angiopoietins in angiogenesis. <i>Cancer Letters</i> , 2013, 328, 18-26.	7.2	523
48	Klf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8). <i>PLoS ONE</i> , 2013, 8, e57329.	2.5	130
49	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 1732-1740.	8.2	166
50	Py2T Murine Breast Cancer Cells, a Versatile Model of TGF $\beta$ -Induced EMT In Vitro and In Vivo. <i>PLoS ONE</i> , 2012, 7, e48651.	2.5	65
51	Concepts of metastasis in flux: The stromal progression model. <i>Seminars in Cancer Biology</i> , 2012, 22, 174-186.	9.6	75
52	EMT as the ultimate survival mechanism of cancer cells. <i>Seminars in Cancer Biology</i> , 2012, 22, 194-207.	9.6	421
53	Molecular networks that regulate cancer metastasis. <i>Seminars in Cancer Biology</i> , 2012, 22, 234-249.	9.6	296
54	Molecular mechanisms of lymphangiogenesis in development and cancer. <i>International Journal of Developmental Biology</i> , 2011, 55, 483-494.	0.6	66

#	ARTICLE	IF	CITATIONS
55	Metastatic Colon Cancer Cells Negotiate the Intravasation Notch. <i>Cancer Cell</i> , 2011, 19, 6-8.	16.8	12
56	Angiopoietin-1 and -2 Exert Antagonistic Functions in Tumor Angiogenesis, yet Both Induce Lymphangiogenesis. <i>Cancer Research</i> , 2011, 71, 5717-5727.	0.9	95
57	Proangiogenic Factor PlGF Programs CD11b+ Myelomonocytes in Breast Cancer during Differentiation of Their Hematopoietic Progenitors. <i>Cancer Research</i> , 2011, 71, 3781-3791.	0.9	32
58	Transcription factor Dlx2 protects from TGF $\beta$ <sup>2</sup> -induced cell-cycle arrest and apoptosis. <i>EMBO Journal</i> , 2011, 30, 4489-4499.	7.8	56
59	Snail1 links transcriptional control with epigenetic regulation. <i>EMBO Journal</i> , 2010, 29, 1787-1789.	7.8	23
60	Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis. <i>PLoS ONE</i> , 2010, 5, e14109.	2.5	45
61	Mechanisms of Motility in Metastasizing Cells. <i>Molecular Cancer Research</i> , 2010, 8, 629-642.	3.4	409
62	Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 55-63.	4.1	42
63	The angiogenic switch in carcinogenesis. <i>Seminars in Cancer Biology</i> , 2009, 19, 329-337.	9.6	438
64	A pro-inflammatory signature mediates FGF2-induced angiogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2083-2108.	3.6	66
65	EMT, the cytoskeleton, and cancer cell invasion. <i>Cancer and Metastasis Reviews</i> , 2009, 28, 15-33.	5.9	1,521
66	Corrupt policemen: inflammatory cells promote tumor angiogenesis. <i>Current Opinion in Oncology</i> , 2009, 21, 60-70.	2.4	97
67	Myeloid Cells Contribute to Tumor Lymphangiogenesis. <i>PLoS ONE</i> , 2009, 4, e7067.	2.5	108
68	Sprouty proteins, masterminds of receptor tyrosine kinase signaling. <i>Angiogenesis</i> , 2008, 11, 53-62.	7.2	208
69	NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. <i>EMBO Journal</i> , 2008, 27, 2603-2615.	7.8	167
70	Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. <i>Nature</i> , 2008, 454, 656-660.	27.8	731
71	Placental Growth Factor-1 Attenuates Vascular Endothelial Growth Factor- $\beta$ -Dependent Tumor Angiogenesis during $\beta$ Cell Carcinogenesis. <i>Cancer Research</i> , 2007, 67, 10840-10848.	0.9	48
72	Neural cell adhesion molecule regulates the cellular response to fibroblast growth factor. <i>Journal of Cell Science</i> , 2007, 120, 4388-4394.	2.0	79

#	ARTICLE	IF	CITATIONS
73	Distinct Roles of Vascular Endothelial Growth Factor-D in Lymphangiogenesis and Metastasis. <i>American Journal of Pathology</i> , 2007, 170, 1348-1361.	3.8	119
74	Division of labour. <i>Nature</i> , 2007, 446, 735-736.	27.8	34
75	Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 587-597.	3.3	220
76	Mouse models of breast cancer metastasis. <i>Breast Cancer Research</i> , 2006, 8, 212.	5.0	252
77	New signals from the invasive front. <i>Nature</i> , 2006, 441, 444-450.	27.8	900
78	Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. <i>EMBO Journal</i> , 2006, 25, 3534-3545.	7.8	327
79	Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. <i>Cancer Cell</i> , 2006, 9, 261-272.	16.8	520
80	Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice. <i>Journal of Leukocyte Biology</i> , 2006, 80, 669-676.	3.3	2
81	A Functional Interaction between Sprouty Proteins and Caveolin-1. <i>Journal of Biological Chemistry</i> , 2006, 281, 29201-29212.	3.4	21
82	Loss of Neural Cell Adhesion Molecule Induces Tumor Metastasis by Up-regulating Lymphangiogenesis. <i>Cancer Research</i> , 2004, 64, 8630-8638.	0.9	80
83	Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. <i>Nature Reviews Cancer</i> , 2004, 4, 118-132.	28.4	1,436
84	Multitasking in Tumor Progression: Signaling Functions of Cell Adhesion Molecules. <i>Annals of the New York Academy of Sciences</i> , 2004, 1014, 58-66.	3.8	136
85	NEW EMBO MEMBER'S REVIEW: Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. <i>EMBO Journal</i> , 2003, 22, 2318-2323.	7.8	226
86	Split personalities: the agonistic antagonist Sprouty. <i>Nature Cell Biology</i> , 2003, 5, 377-379.	10.3	85
87	Sprouty proteins: antagonists of endothelial cell signaling and more. <i>Thrombosis and Haemostasis</i> , 2003, 90, 586-590.	3.4	35
88	Cadherins and the tumour progression: is it all in a switch?. <i>Cancer Letters</i> , 2002, 176, 123-128.	7.2	182
89	Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. <i>Cancer Research</i> , 2002, 62, 603-8.	0.9	54
90	N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. <i>Nature Cell Biology</i> , 2001, 3, 650-657.	10.3	276

#	ARTICLE	IF	CITATIONS
91	Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2001, 1552, 39-45.	7.4	177
92	Mammalian Sprouty-1 and -2 Are Membrane-Anchored Phosphoprotein Inhibitors of Growth Factor Signaling in Endothelial Cells. <i>Journal of Cell Biology</i> , 2001, 152, 1087-1098.	5.2	257
93	Molecular mechanisms of tumor angiogenesis and tumor progression. , 2000, 50, 63-70.		117
94	Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic $\beta^2$ tumor cells. <i>Nature Medicine</i> , 1999, 5, 286-291.	30.7	124
95	The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. <i>Trends in Biochemical Sciences</i> , 1999, 24, 73-76.	7.5	670
96	The implications of angiogenesis on tumor invasiveness. , 1998, 2, 21-23.		5
97	A causal role for E-cadherin in the transition from adenoma to carcinoma. <i>Nature</i> , 1998, 392, 190-193.	27.8	1,559
98	The Tumor-Suppressor Function of E-Cadherin. <i>American Journal of Human Genetics</i> , 1998, 63, 1588-1593.	6.2	129
99	Novel forms of acidic fibroblast growth factor-1 are constitutively exported by beta tumor cell lines independent from conventional secretion and apoptosis. <i>Angiogenesis</i> , 1997, 1, 55-70.	7.2	9
100	Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during $\beta^2$ cell tumorigenesis. <i>Nature Genetics</i> , 1995, 10, 196-201.	21.4	123
101	A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. <i>Nature</i> , 1994, 369, 414-418.	27.8	385